Muscular Dystrophy Canada
Institute of Musculoskeletal Health and Arthritis
| Important Dates | |
| Opportunity Launched | June 2006 |
| Content Last Updated | November 1, 2006 (Important Dates) |
| September 15, 2006 | Letter of Intent Deadline - Letter of Intent must be courier stamped by this date. (Updated: 2006-09-08) |
| September 30, 2006 | Letter of Intent Decision. (Updated: 2006-09-08) |
| January 15, 2007 | Full applications must be courier stamped by this date. (Updated: 2006-11-01) |
| February 28, 2007 | Anticipated notification of decision. |
| March 15, 2007 | Anticipated start date. (Updated: 2006-11-01) |
| Funds Available | |
|
CIHR's contribution to the amount available for this initiative is subject to availability of funds voted annually to CIHR by parliamentary appropriations, and the conditions that may be attached to them.
| |
| Summary | |
|
Muscular Dystrophy Canada (MDC) and the Canadian Institutes of Health Research - Institute of Musculoskeletal Health and Arthritis (CIHR-IMHA) are pleased to announce the "Rachel Fund'' for research relating to Myotonic Dystrophy. The Rachel Fund is an initiative to advance research on Myotonic Dystrophy, initiated through a $900,000 donation provided by Mr. Al Libfeld, a generous donor to Muscular Dystrophy Canada. With an additional $50,000 to $250,000 over five years provided by the CIHR Institute of Musculoskeletal Health and Arthritis, the Fund has been increased to $1.150 million. | |
Partners
Objectives
Eligibility
Allowable Costs
Review Process and Evaluation Criteria
General CIHR Guidelines
Conditions of Funding
Communications Requirements
Monitoring, Performance Measurement and Evaluation
How to Apply
Contact Information
Description of Partners
The MDC and CIHR-IMHA are dedicated to identifying and developing collaborations with other CIHR institute(s), branch(es) or office(s), funding organizations and stakeholders to enhance the availability of funding for this strategic initiative, and to create, where appropriate, opportunities for knowledge exchange and translation related to the scope of this particular initiative. Applicants are invited to visit the Descriptions of Partners to find a list of partners and their respective mandates and/or strategic interests. This list will continue to evolve as new partners join in this initiative. The specific research foci and requirements for each partner are outlined in the section "Objectives".
The objective of this initiative is to fund research that meets one or more of the following criteria:
The Institute of Musculoskeletal Health and Arthritis encourages researchers across disciplines within the Arthritis, Bone, Skin, Muscle, Oral Health and/or Rehabilitation Research communities, and across all four of CIHR research pillars to develop research in areas covered by IMHA's three research priorities as they relate to myotonic dystrophy:
Eligibility criteria for all CIHR research funding programs apply. The business office of the institution of an eligible Nominated Principal Applicant generally administers CIHR funds. Please refer to the Eligibility Requirements for CIHR Grants and Awards regarding the eligibility requirements for individuals and institutions.
Randomized Controlled Trials (RCTs) will not be considered under this RFA.
Specific Eligibility Requirements
Eligibility requirements specific to this Request for Applications include the following:
Applicants should review the Tri-Agency (CIHR, NSERC and SSHRC) financial administration guidelines Use of Grant Funds for a complete listing and description of allowable costs and activities.
The full application must provide a detailed justification of all costs.
The review process will consist of both a relevance review as well as scientific peer review.
All LOIs will be reviewed for relevance by the Relevancy Peer Review Committee (RPRC) (to be formulated in collaboration with the partners) to ensure that only grants relevant to the intentions of the initiative are forwarded for scientific review by the Scientific Peer Review Committee (SPRC). In order to conduct relevance review, the partners will have access to anonymized project titles and summaries.
The review of applications for relevance to the strategic initiative will have no impact on the scientific peer review process.
A combined MDC / CIHR scientific peer review committee will evaluate the full applications. Committee members are selected based on suggestions from many sources including the institute(s) / portfolio(s) and partner(s), following CIHR's Policy on Confidentiality, Conflict of Interest and Privacy Issues in Peer and Relevance Review (CCIP). For information on CIHR's peer review process in general, see Peer Review.
Peer review will be conducted in accordance with The CIHR Peer Review Process: Policies and Responsibilities of Grants Committee Members, including the standard evaluation criteria described under "Factors for Assessment" (section 6.2).
Upon completion of peer review, the partners will receive the ranking list, merit scores (ratings) and recommendations on funding level and award term for the applications that fall in the fundable range and have been determined to be relevant to the specific research areas and objectives of the initiative. The list will be used for funding decision-making purposes and will remain anonymous.
In addition, the following evaluation criteria specific to this Request for Applications will apply. CIHR recognizes that applications will emphasize different approaches to research and to knowledge translation, therefore reviewers and committees are expected to weight criteria such as these differently from one application to another.
Knowledge Translation and Exchange (KTE) is an integral component of IMHA's strategic plan.
KTE is defined as the exchange, synthesis and ethically sound application of research findings within a complex set of interactions among researchers and knowledge users - to accelerate the capture of the benefits of research for Canadians through improved health, more effective services and products, and a strengthened health care system.
In order to encourage researchers to partake in KTE, IMHA is piloting a KTE module through which up to $25K of additional funds might be provided to those researchers who choose to apply for them. For further info, please refer to the KTE module.
This Request for Applications will follow the General Guidelines for Grant Programs. Applicants are encouraged to demonstrate the use of gender and sex-based analysis in applications.
All conditions specified in CIHR General Grants and Awards Policies shall apply to applications funded through this Request for Applications. Conditions cover areas such as Applicant and Institutional Responsibilities, Ethics, Official language policy, Access to Information and Privacy Acts, and Acknowledgement of CIHR Support. Successful applicants will be informed of any special financial conditions prior to the release of funds or when they receive CIHR's Authorization for Funding (AFF) document.
In addition to CIHR standard guidelines and requirements, the following special conditions shall apply:
Recipients of this partnership funding must provide to MDC and CIHR a one page lay report suitable for publication, outlining the status of your project to date, submitted at the completion of each year of funding.
Access to Information Act and Privacy Act, and the Personal Information Protection and Electronic Documents Act (PIPEDA)
All personal information collected by CIHR about applicants is used to review applications, to recruit reviewers, to administer and monitor grants and awards, to compile statistics, and to promote and support health research in Canada. Consistent with these purposes, applicants should also expect that information collected by CIHR may be shared as described in Use and Disclosure of Personal Information Provided to CIHR for Peer Review.
CIHR as a federal entity is subject to the Access to Information Act and the Privacy Act, therefore the requirements of these two statutes will apply to all information located in CIHR's premises including, without limitation, cost-sharing agreements related to this Request for Applications and all matters pertaining thereto.
While respecting the application of the Privacy Act to federal entities, all signing parties involved in a collaborative agreement will also be bound by the Personal Information Protection and Electronic Documents Act (PIPEDA). All personal information (as identified by the PIPEDA) collected, used or disclosed in the course of any commercial activity under collaborative agreements related to the Request for Applications will be collected, used and disclosed in compliance with the PIPEDA.
Grant recipients are required to acknowledge funding through the "Rachel Fund" an initiative of Muscular Dystrophy Canada (MDC) and CIHR-IMHA in any communication or publication related to the project. See CIHR General Grants and Awards Policies, Acknowledgement of CIHR's Support for details on CIHR's communication requirements. The contributing institutes / partners will be identified on the Authorization for Funding and decision letter.
CIHR is committed to demonstrating results to Canadians for the money invested in health research. Therefore, processes for monitoring progress and appropriate use of funds, as well as for performance measurement and program evaluation are in place. As a result, funding recipients must:
The application process is comprised of two stages: 1) Letter of Intent (LOI), and 2) Full Application.
1) Letter of Intent (LOI)
In the first stage of the application process the Nominated Principal Applicant is required to submit a Letter of Intent.
Applicants are advised to follow the instructions on the Acceptable Application Module Formats page which outlines formatting requirements for the letter and attachments.
The Letter of Intent must include:
a) The Registration pages of the CIHR Research Module:
To generate the Registration pages, you must access the CIHR Web Forms. When creating a new application, select "Operating" under "Grant Programs" and complete the following six sections of the Research Module web form. Print the "Registration Pages Only."
b) A cover page of maximum one page (free form; a standard form is not available for the cover page) indicating:
c) Proposal.
In a maximum of five pages (not including references), the proposal must outline clearly each of the elements below:
d) Reference: a short bibliography (maximum one page) of any references cited in the proposal.
Any additional materials will not be sent to the review committee; this includes letters of support, figures not included in the proposal, updates on publications, updates on other support received, letters confirming academic appointment, reprints, etc.
Send the original Letter of Intent and six copies by courier to:
RE: "RACHEL FUND for research relating to Myotonic Dystrophy"
MUSCULAR DYSTROPHY CANADA
2345 Yonge St, Suite 900
Toronto, Ontario M4P 2E5
A response to the LOI will be emailed to the Nominated Principal Applicant confirming receipt of the LOI.
2) Full Application
Review the application instructions provided in How to Apply for Funding.
Select "Operating Grants" (Application) from the Grant Programs Application Packages.
Additional instructions must be followed for this RFA:
Send the completed application packages by courier to:
RE: "RACHEL FUND for research relating to Myotonic Dystrophy"
MUSCULAR DYSTROPHY CANADA
2345 Yonge St, Suite 900
Toronto, Ontario M4P 2E5
For questions on CIHR funding guidelines, how to apply, contact:
Tamara Marshall
Program Delivery Officer
Canadian Institutes of Health Research
Telephone: (613) 941-0861
Fax: (613) 954-1800
Email: tmarshall@cihr-irsc.gc.ca
For questions about this initiative and research objectives contact:
Wyn Chivers
National Executive Director
Muscular Dystrophy Canada
2345 Yonge Street, Suite 900
Toronto, ON M4P 2E5
Telephone: (416) 488-0030 ext. 130
Fax: (416) 488-7523
Email: wyn.chivers@muscle.ca
Sophia Tsouros
Project Manager / Analyst
CIHR - Institute of Musculoskeletal Health and Arthritis
Telephone: (613) 954-3469
Fax: (613) 954-1800
Email: stsouros@cihr-irsc.gc.ca
Note: Additional partners, including partners from industry and the private sector are expected.
CIHR - Institute of Musculoskeletal Health and Arthritis
The goal of the CIHR - Institute of Musculoskeletal Health and Arthritis is to support research to sustain health and enhance quality of life by eradicating the pain, suffering and disability caused by arthritis, musculoskeletal, oral and skin conditions.
Muscular Dystrophy Canada
Muscular Dystrophy Canada is a national voluntary agency committed to:
